Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendationEric Legius, C. Oliver Hanemann, Ludwine Messiaen et al.|Genetics in Medicine|2021Cited by 766
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Michael J. Fisher, Elizabeth K. Schorry et al.|Neuro-Oncology|2014Cited by 147
Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trialMichael J. Fisher, D. Wade Clapp|Nature Medicine|2021Cited by 95
Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II studyBrian Weiss, Michael J. Fisher, Brigitte C. Widemann et al.|Pediatric Blood & Cancer|2013Cited by 87
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J. Ullrich, Mark W. Kieran, Sanjay P. Prabhu et al.|Neuro-Oncology|2020Cited by 82